Is Medicamen Biotec overvalued or undervalued?

As of 13 November 2025, the valuation grade for Medicamen Biotec has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 59.70, an EV to EBITDA of 39.67, and a PEG ratio of 2.95, all of which indicate a high valuation relative to earnings and growth potential.
In comparison to its peers, Medicamen Biotec's PE ratio significantly exceeds that of Sun Pharma (36.15) and is also higher than Torrent Pharma (59.84), both of which are categorized as very expensive. Notably, Cipla, which is rated attractive, has a much lower PE ratio of 22.65, suggesting that Medicamen Biotec's valuation is not justified when compared to more reasonably priced competitors. Additionally, while Medicamen Biotec has seen a strong short-term return of 4.69% over the past week compared to the Sensex's 1.40%, its year-to-date performance is concerning with a decline of 18.07%, further supporting the argument for its overvaluation.